Cristiana A. Costa

Journal Article Clin Cancer Res · October 15, 2019 PURPOSE: Bendamustine and rituximab (BR) has been established as a superior frontline therapy over R-CHOP in the treatment of follicular lymphoma (FL). Yttrium-90 Ibritumomab tiuxetan (90YIT) is an effective consolidation strategy after chemotherapy induct ... Full text Link to item Cite

–positive relapsed and refractory, diffuse large ‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy

Journal Article Cancer · November 15, 2017 BACKGROUNDThe impact of MYC proto‐oncogene, basic helix‐loop‐helix (MYC) translocations (with or without additional rearrangements involving the B‐cell lymphoma 2 [BCL2 Full text Cite

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

Journal Article Journal of Clinical Oncology · July 10, 2017 Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce th ... Full text Cite

Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies

Journal Article American Journal of Hematology · February 2017 AbstractThe outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), r ... Full text Cite

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Conference Blood · December 2, 2016 AbstractBackground:Y90-Ibritumomab tiuxetan (90YIT) is approved for use for follicular lymphoma (FL) patients who have achieved a complete or partial response to frontline ch ... Full text Cite